MedTrace Logo

Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

NCT07034053 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-06-26

No results posted yet for this study

Summary

This phase 1/2 study will evaluate the maximum tolerated dose, efficacy, and safety of clofarabine in patients with advanced or metastatic urothelial cancer.

Conditions

  • Advanced Urothelial Carcinoma
  • Metastatic Urothelial Cancer

Interventions

DRUG

Clofarabine

Patients receive i.v. clofarabine in a dose-escalation regimen

Sponsors & Collaborators

  • Ekaterina Laukhtina

    lead OTHER

Principal Investigators

  • Shahrokh F. Shariat Prof. Dr., Professor · Department of Urology, Medical University of Viernna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-24
Primary Completion
2028-11-30
Completion
2028-11-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07034053 on ClinicalTrials.gov